Anavex stock plummets 50% after Alzheimer's drug faces EU regulatory rejection

Anavex Life Sciences has faced a sharp decline in its stock price after a major regulatory setback. The company withdrew its European marketing application for blarcamesine, an Alzheimer's treatment, on March 25. Since then, shares have dropped by nearly 50% compared to their year-to-date peak. The trouble began when the European Medicines Agency (EMA) signalled it would not approve blarcamesine. Regulators raised concerns about the existing data, suggesting additional trials or complex analyses might be needed. This decision prompted Anavex to withdraw its application voluntarily.

The stock reacted immediately, falling between 29% and 37% in the week after the announcement. The decline pushed the company's relative strength index into the mid-20s, a level considered deeply oversold. Despite this, analysts still rate the stock as a 'Moderate Buy,' with an average price target of $22—nearly nine times its current value over the next year.

Blarcamesine had shown promise in earlier trials, with Phase 2b/3 results indicating a 36% improvement in Alzheimer's symptoms and reduced brain atrophy. However, the EMA's rejection delays the drug's commercialisation and raises concerns about future approvals in the U.S. A negative EMA opinion often signals similar challenges with the FDA, potentially limiting global revenue.

Financially, Anavex remains stable, holding around $131 million in cash and no debt. This funding is expected to cover operations for over three years, even without new revenue from blarcamesine. The withdrawal of the EU application marks a significant delay for Anavex's lead drug. While the company has strong cash reserves, the regulatory hurdles may push back commercial plans. Investors are now watching whether further trials or adjustments can address the EMA's concerns.